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Approximately 350 million patients of hepatitis B and 170 million patients of Hepatitis C are present 
worldwide according to WHO. Many risk factors are involved in the transmission of theses deadly viral 
infections but blood transfusion in Beta thalassemic patients is working with two faces, one as remedy 
and the other is key risk factor in the spread of silent killers. Thalassemia patients registered in Combine 
Military Hospital (CMH) Rawalakot and Sheikh Khalifa Bin Zayed Al-Nahyan Hospital, Muzaffarabad 
Azad Jammu and Kashmir Pakistan were studied for the viral hepatitis B and C prevalence. A total of 
303 (including 164 males and 139 females) individuals, aged between 1 and 12 years were studied. All 
the understudy participants were interviewed through questionnaire method. After taking written consent 
from each participant or guardian, 5 ml of blood was collected from each participant and brought to the 
working laboratory for HBV and HCV screening through ICT kit method. All ICT positive samples were 
IXUWKHUFRQ¿UPHGWKURXJK(/,6$,QGLYLGXDOVZHUHIRXQGSRVLWLYHIRUERWKKHSDWLWLV%VXUIDFH
Antigen (HBsAg) and Anti hepatitis C antibody (Anti-HCV antibody) after initial screening with no 
FRLQIHFWLRQRIERWKGLVHDVHV2XWRIWRWDOLQIHFWHGLQGLYLGXDOVZHUHIRXQG+%V$JSRVLWLYH
DQGZHUHIRXQGDQWL+&9SRVLWLYH$OOWKH,&7SRVLWLYHLQGLYLGXDOVZHUHIXUWKHUFRQ¿UPHGE\
TXDQWLWDWLYH(Q]\PH/LQNHG,PPXQRVRUEHQW$VVD\(/,6$DQGLQGLYLGXDOVZHUHFRQ¿UPHG
IRUERWKKHSDWLWLV%DQG&LQFOXGLQJ+%V$JSRVLWLYHDVZHOODVDQWL+&9DQWLERG\
SRVLWLYH LQGLYLGXDOV:H FDQ FRQFOXGH WKDW  SUHYDOHQFH RI KHSDWLWLV % DQG & DPRQJ WKDODVVHPLF
SDWLHQWVLVDQDODUPLQJKHDOWKFRQFHUQZKLFKGLUHFWO\LQGLFDWHVWRSD\DWWHQWLRQIRUHQVXULQJVDIH
blood transfusion.
A major risk for the patients of transfusion dependent ȕWKDODVVHPLD LVGHYHORSLQJEORRG LQIHFWLRQVDPRQJ
which, hepatitis B and C are the most common (Jafroodi et 
al., 2015). It is well-known that hepatitis C virus is a major 
cause of post transfusion hepatitis infection (Farooq et al., 
) which may also lead to liver cancer or cirrhosis 
(Ataei et al., 2012).
The cause of post-transfusion hepatitis as well 
aschronic liver failure in most of countries is hepatitis C 
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virus. The factor involved in the increase of survival with 
hereditary hemolytic anemia is blood transfusion but it is 
also one of many causes of viral hepatitis transmission 
among thalassemia patients (Mehta et al., 2017). 
Thalassemia patients are always at a high risk of diseases 
transmitted via blood transfusion and post transfusion 
hepatitis B and C present a major problem round the globe 
(Ahmadi-Ghezeldasht et al), hence, in thalassemics 
patient, treatment of hepatitis C (HCV) is quite hard due to 
the haemolytic side effects of therapy (Sajjad et al., 2017).
Blood transfusion is the major cause of hepatitis B 
and Confections in many parts of the world especially 
in developing countries where the screening system is 
$ % 6 7 5 $ & 7
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not much established. In Scandinavia, the prevalence of 
KHSDWLWLVLQWUDQVIXVLRQUHFLSLHQWVZDV(GJUHQet al., 
 DQG LQ 5ZDQGDLW ZDV  Twagirumugabe et 
al., 2017 3DWLHQWV ZLWK ȕWKDODVVHPLD KHPRSKLOLD DQG
uremia, who receive multiple blood transfusions, are at an 
increased risk of transfusion related diseases (Tafesse et 
al., 2017RXWRIWUDQVIXVLRQGHSHQGHQW
thalassemia children were found HCV positive in a 
descriptive cross sectional study conducted by Ali et al. 
(2016)LQ3DNLVWDQ,QDQRWKHUVWXG\EHWDWKDODVVVHPLD
major children tested for hepatitis C virus out of which 
FKLOGUHQZHUHIRXQGSRVLWLYHHussain et al., 
). Another study found hepatitis G virus in Pakistani 
children with transfusion dependent beta-thalassemia 
major (Moatter et al., 1999). The rate of hepatitis B and C 
were found to be very high among thalassemia patients after 
acquiring some molecular methods (Kadhim et al., 2017). 
According to the Pakistan Health and Research Council, 
a national survey showed that the frequency of HCV and 
+%9LQIHFWLRQVLQ3DNLVWDQ¶VJHQHUDOSRSXODWLRQZDV
DQGUHVSHFWLYHO\3UHYDOHQFHRI+&9LQIHFWLRQDORQH
UDQJHVIURPWRLQ3DNLVWDQUHSRUWHGO\,QWKHYLHZ
of that, about 10 million people in Pakistan are infected 
with HCV (Ahmed et al., 2016).
7KHSUHVHQWVWXG\ZDVDLPHGWR¿QGRXWSUHYDOHQFH
of hepatitis B and C among thalassemia patients with 
UHVSHFWHG WR JHQGHU DQG DJH DV ZHOO DV WR ¿QG RXW
associated risk factors other than blood transfusion which 
are involved in the spread of these silent killers. 
Materials and Methods
The study was approved by the Directorate of 
Advance Studies and Research (DASR), which have 
authority to approve research and deal ethical issues in 
University of Azad Jammu and Kashmir, Muzaffarabad.
Thalassemia patients registered in Combine Military 
Hospital (CMH) Rawalakot and Sheikh Khalifa Bin Zayed 
Al-Nahyan Hospital, Muzaffarabad, Azad Jammu and 
Kashmir Pakistan were studied for the viral hepatitis B and 
C prevalence. A total of 303 (including 164 males and 139 
females) individuals, aged between 1 and 12 years were 
studied. All the understudy participants were interviewed 
WKURXJKTXHVWLRQQDLUHPHWKRG$¿OOHGDQGVLJQHGFRQVHQW
was collected from each participant or guardian. The 
consent form based upon collection of general information 
(age, sex and locality) and for risk factor assessment.
Blood samples (5ml) were collected from each 
participant and injected in the gel tube (Biotube Gel 
Clot Activator). Serum was separated by centrifugation. 
(DFK VHUXP VDPSOH ZDV ODEHOHG DQG VWRUHG DW &
The hepatitis B surface antigen (HBsAg) and hepatitis C 
virus antibody (anti-HCV) were detected by using ICT kit 
PHWKRG WKURXJK,&7GHYLFHV 6'%,2/,1(+%V$JDQG
Anti-HCV kits). Moreover, all the initially HBsAg and 
DQWL+&9 SRVLWLYH LQGLYLGXDOV ZHUH IXUWKHU TXDQWL¿HG
for viral antigens and antibodies respectively through 
TXDQWLWDWLYH(/,6$ZLWKWKHFXWRIIYDOXH1RQ5HDFWLYH
(TXLYRFDODQG5HDFWLYH!SURYLGHG
ZLWKGLDJQRVWLFNLWIRU+%V$JDQGDQWL+&9E\WKH/LQHDU
&KHPLFDOV6/6SDLQ
Data was analyzed through GraphPad Prism (Version 
 WR FDOFXODWH WKH PHDQ DJH ZLWK  &RQ¿GHQFH
Interval), standard deviation and Chi-square test was used 
WR GHWHFW WKH VLJQL¿FDQFH OHYHO RI GLIIHUHQW ULVN IDFWRUV
involved in the spread of hepatitis B and C in thalassemia 
patients.
Fig. 1. Comprehensive prevalence (A) and age wise 
frequency distribution (B) of hepatitis B and C in 
thalassemia patients of Azad Kashmir, Pakistan.
Results
)RUWKHSUHVHQWVWXG\WRWDOȕWKDODVVHPLDSDWLHQWV
were screened through immune-chromatography devices 
,&7 LQFOXGLQJ   PDOH DQG  
IHPDOH LQGLYLGXDOV   LQGLYLGXDOV ZHUH IRXQG
)6KD¿TXHet al.
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positive for both hepatitis B surface antigen (HBsAg) and 
Anti hepatitis C antibody (anti-HCV antibody) after initial 
screening with no coinfection of both diseases. Out of 25 
WRWDO LQIHFWHG LQGLYLGXDOV  ZHUH IRXQG +%V$J
SRVLWLYHPDOHDQGIHPDOHDQGZHUHIRXQG
anti-HCV positive (3 male and 17 female). 
All the ICT positive individuals were further 
FRQ¿UPHGE\TXDQWLWDWLYHHQ]\PHOLQNHGLPPXQRVRUEHQW
DVVD\ (/,6$ DQG ZH IRXQG  LQGLYLGXDOV
FRQ¿UPHGIRUERWKKHSDWLWLV%DQG&LQFOXGLQJ
+%V$J SRVLWLYH  PDOH DQG  IHPDOH DV ZHOO DV 
DQWL+&9DQWLERG\SRVLWLYHPDOHDQGIHPDOH
individuals.
7KH PDOH SRSXODWLRQ ZDV IRXQG ZLWK  +%V$J
SUHYDOHQFHDVFRPSDUH WRSUHYDOHQFHRI+%V$J LQ
female population. In case of Anti-HCV prevalence, the 
IHPDOHVZHUHIRXQGPRUHSUHYDOHQWZLWKSUHYDOHQFH
DVFRPSDUHWRRI+%V$JLQPDOHSRSXODWLRQFig. 1A).
For determining prevalence of hepatitis B and C 
DPRQJ ȕWKDODVVHPLD SDWLHQWV WKH DJHZLVH GDWD ZDV
analyzed by using GraphPad Prism (Version 5.0) software 
and the population was divided in to two age groups, 1-6 
years and 7-12 years, respectively. Standard deviation for 
the total population was found 3.13 and mean age with 
 &RQ¿GHQFH ,QWHUYDO ZDV IRXQG  IRU WKH
total population. Moreover, the age group 7-12 years was 
IRXQGZLWKKLJKHUSUHYDOHQFHRIERWKKHSDWLWLV%
DQGKHSDWLWLV&DVFRPSDUHWRDJHJURXSVRI
years. This is due to the increase rate of multi transfusion 
with the increase of age in the case of thalassemia because 
the blood transfusion is the key risk factor involve in the 
spread of hepatitis B and C world-wide (Table I; Fig. 1B).
For the present study risk factors were assessed 
through a questions based proforma from each participant 
or from the guardian on the behalf of participants. Data 
was analyzed through two sided chi-square test (at p 
0.05) by using GraphPad Prism (version 5.0). We found 
VLJQL¿FDQW UHODWLRQVKLSRIKHSDWLWLV%DQG& VSUHDGZLWK
family hepatitis history and dental treatment. Treatment 
IURPD ORFDO3UDFWLFLDQZDV IRXQGQRW VLJQL¿FDQWZLWKS
value of 0.0625 regarding to spread of hepatitis B and C in 
thalassemia patients. Table II shows all the details related 
to risk factors assessment in the thalassemia patients other 
than blood transfusion. 
7DEOH , $JHZLVH SUHYDOHQFH RI KHSDWLWLV % DQG &
DPRQJȕWKDODVVHPLDSDWLHQWV
Age 1RRI
Ind.
SD Mean age 
ZLWK&,
HBsAg 
+ve
$QWL+&9
+ve
01-06 213    
07-12 90 1.37   
Total Ind. 303 3.13   
Ind., individuals, SD, standard deviation.
Discussion
In the present study, the sero-prevalence of HBV 
PDUNHUV +%V$J DQG DQWL+%& ZDV  LQ EHWD
thalassemia patients living in Azad Kashmir which 
indicated a high exposure rate. While it was observed that 
WKHSUHYDOHQFHRI+%V$JZDV1RDQWL+%FGHWHFWLRQ
procedure was used to study the selected population. 
In a similar study conducted by Jang et al. (2017) 140 
patients were tested, out of which only one patient was 
found positive for HBsAg that accounts for a prevalence 
RIDQGDQWL+&9ZDVIRXQGWREH:KLOHLQ
WKHSUHVHQWVWXG\ȕWKDODVVHPLDSDWLHQWVZHUHVFUHHQHG
in total through immune-chromatography devices (ICT), 
LQZKLFK ZHUHPDOHDQG ZHUH
female individuals. Among 303 beta thalassemia patients 
 LQGLYLGXDOVZHUH IRXQG WREHSRVLWLYH IRUERWK
hepatitis B surface antigen (HBsAg) and anti-hepatitis 
C antibody (anti-HCV antibody) that were believed to 
be uninfected after initial screening. Out of 25 infected 
LQGLYLGXDOVZHUHFRQ¿UPHGDV+%V$JSRVLWLYH
PDOHVDQGIHPDOHVDQGZHUHIRXQGDQWL
HCV positive (3 males and 17 females). While the average 
age of patient was 1 to 12 years. A higher prevalence of 
ERWKKHSDWLWLV%DQGKHSDWLWLV&LQIHFWLRQV
was observed in the age group of 7-12 years. Another 
study was conducted in Pakistan in which total 95 patients 
REVHUYHG ZHUH IRXQG ȕWKDODVVHPLD PDMRU  DQG
ȕWKDODVVHPLD LQWHUPHGLD $PRQJ WKHVH  
were found positive for anti-HCV antibodies and three for 
hepatitis B surface antigen (Din et al., 2014).
7DEOH,,5LVNIDFWRUVDVVHVVPHQWUHJDUGLQJWRVSUHDGRIKHSDWLWLV%DQG&
Risk factors Response 
options
Overall 
responses
Responses of 
diseased 
Responses of 
QRQGLVHDVHG
&KLVTXDUHYDOXH
3YDOXHWZRVLGHG
6WDWLVWLFDOVLJQL¿FDQFH
DW3
Hepatitis history in the 
family?
Yes 2 1 1 0.0313 Yes
No 301 24 277
Dental treatment? Yes 1 1 0  Yes
No 302 24 
Treatment from a local 
practician?
Yes 106 13 93 0.0625 No
No 197 12 
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It is revealed from other studies that the chances of 
LQIHFWLRQVLJQL¿FDQWO\ULVHZLWK WKH LQFUHDVLQJDJHDV WKH
demand of blood transfusions increases with the passage of 
time (Manisha et al., 20156LPLODU¿QGLQJVZHREVHUYHG
LQRXUVWXG\ZKHUHDKLJKHUSUHYDOHQFHRI+9&
DQG +%9  LQIHFWLRQV ZHUH REVHUYHG LQ \HDU
age group due to the increase rate of multiple transfusions 
to meet the demand in case of thalassemia.
According to a study, 206 individuals were tested 
IRUDQWL+&9WKURXJK(/,6$RIWKHSDWLHQWV
were found anti-HCV positive (Boroujerdnia et al., 2009). 
While in the present study the total population was 303, the 
standard deviation for the total population was found 3.13 
DQG PHDQ DJH ZLWK  &RQ¿GHQFH ,QWHUYDO ZDV IRXQG
0RUHRYHUDIWHU(/,6$LQGLYLGXDOVZHUH
FRQ¿UPHG IRU KHSDWLWLV & LQIHFWLRQ ZKLFK LV WRR ORZ DV
FRPSDUHGWRSUHYDOHQFHRIKHSDWLWLV&IRXQGLQWKH
study of Boroujerdnia et al. (2009).
Conclusions and recommendations
7KH KLJK  SUHYDOHQFH RI KHSDWLWLV % DQG &
in a vulnerable population such as thalassemic patients 
is an alarming health concern that directly indicates that 
attention should be paid to ensure pre-screened blood 
transfusion. 
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